Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
IPO Year: 2007
Exchange: NASDAQ
Website: accuray.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | $9.00 | Buy | ROTH MKM |
| 6/23/2022 | $7.50 | Buy | B. Riley Securities |
| 12/22/2021 | $7.50 | Buy | Loop Capital |
4 - ACCURAY INC (0001138723) (Issuer)
3 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
3 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00
B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
SD - ACCURAY INC (0001138723) (Filer)
10-Q - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
10-Q - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
S-8 - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r
Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S
MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the
MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California. Management will participate in a fireside chat on Tuesday, March 18, 2025, at 9:30am PT / 12:30pm ET, and will be available for one-on-one meetings with investors. A live webcast of the fireside chat can be accessed here and on the Accuray website at investors.accuray.com. The webcast replay of the presentation will be available on the company's website about one hour
MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str
MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. Shandong Cancer Hospital and Institute was the first hospital in China to receive the new Tomo C System which has already demonstrated its value by expanding clinical capabilities and the opportunity to offer potentially curative treatment to more people diagnosed with cancer. This first cohort of Tomo C System treatments also represent a milestone for Accuray wh
MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has
MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the
MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str
MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis., Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2024. "We continue to make solid progress in the execution of our strategic growth agenda and performed better than expected in the first quarter and are on track to deliver our fiscal 2025 plan. Our performance in the China region was strong and we saw significant interest in the recently introduced Accuray Tomo® C System and growth in our service business. I could not be mor
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 6, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024. Third Quarter Fiscal 2024 Summary Net revenue of $101.1 million decreased 14 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.4 million, which represented a 13 percent decrease from the same period in the prior fiscal year.GAAP net loss was $6.3 million, as compared to GAAP net income of $0.6 million in the same period in the prior fiscal year. Adjusted
MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (international),
MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has
MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024
SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
SUNNYVALE, Calif., June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including the global accounting organization and associated budgetary and administrative operations, as well as financial and regulatory compliance. He will report to Accuray senior vice president & chief financial officer Ali Pervaiz. Mr. Palomba is a skilled executive with more than 30 years of accounting and f
SUNNYVALE, Calif., May 17, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022. Mr. Chalke will have responsibility for the global commercial, product development, R&D and engineering functions for the company reporting to Accuray president and forthcoming CEO, Suzanne Winter. Mr. Chalke brings more than 25 years of medical device expertise in commercialization, business development and operations, spanning multiple healthcare industry segmen
SUNNYVALE, Calif., Aug. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021. With Ms. Nishimura's appointment, the Accuray Board will consist of nine members. Ms. Nishimura also currently serves as an Independent Director on the Boards of SI-BONE, Inc., and MobileODT, and as a Board advisor to Tristel, plc. A commercial business executive with more than 25 years of global medical device industry experience, Ms. Nishimura has deep product commercialization experience across a broad range of innovative medical technologies.
SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021. In this new role, Dr. Pignol will lead the company's scientific and clinical research activities, develop strategic collaborations with global key opinion leaders, evaluate new technologies and serve as the executive representative with important industry partners including medical societies, regulatory and legislative agencies that influence healthcare policy and reimbursement.
SUNNYVALE, Calif., Feb. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott, M.D., MBA to the company's Board of Directors, effective as of February 12, 2021. Dr. Scott brings significant experience as a physician executive with invaluable global expertise in healthcare analytics and technology. Dr. Scott is currently on the faculties at the University of Massachusetts, Amherst, Isenberg School of Management and Jefferson University, College of Population Health where he teaches healthcare quality, patient safety, and performance improvement. Previously, Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health, where he s